[Below are the Areas of Interest for consideration for GSK’s Assets:]

For belantamab mafodotin these include (updated August 2026):

Combination Therapies:
Belamaf in combination with novel treatment options (e.g. CeLMoDs) in late-stage development in Multiple Myeloma where there is no ongoing research
•   Induction with T-cell engagers followed by low-dose belamaf maintenance therapy
•   Innovative combinations with a strong scientific rationale aimed at addressing areas of high unmet need.

Additional Therapeutic Targets
Role of BCMA in autoimmune diseases

Pipeline asset (s) proposals may be considered where there is strong rational and data delivery aligns with clinical development of the asset.


[For Momelotinib these include (updated January 2026):]

Combination of Momelotinib with novel clinical stage assets with disease modifying potential, not limited to:

•   Anti-HJV (e.g., DISC-0974)
•   Anti-CALR therapies
•   MDM2 inhibitors (e.g., Navtemadlin)
•   Telomerase inhibitors (e.g., Imetelstat)
•   TGF modulators (e.g., elritercept)
•   CK0804

Note: Proposals to address other hematologic malignancies may be considered for those with extraordinary scientific rationale (case-by-case)
Combination strategies in VEXAS syndrome:
•   IL-1 / IL-6 inhibitors
•   HMAs (oral)
•   Next-generation targeted therapies

[For Dostarlimab these include (updated June 2026):]

Endometrial Cancer
1.   Translational research on anti-PD-(L)1 resistance
2.   ctDNA clinical utility in EC and for IO monitoring & treatment optimization
3.   IO combination approaches for MMRp/MSS EC

GI
1.   Stage I and II dMMR/MSI-H rectal cancer
2.   Optimal duration of therapy (i.e. retreatment)
3.   Investigation of adjuvant IO in dMMR/MSI-H locally advanced colon cancer
4.   Investigation of optimal clinical staging techniques and improvements in locally advanced colon cancer

Head and Neck
1.   Investigation of novel combinations (e.g. B7H3)
2.   Investigation of nasopharyngeal carcinoma

[For Velzatinib these include (updated July 2026):]

Unresectable and metastatic GIST
1. Velzatinib combination with other agents including novel agents and chemotherapy/ IO agents
2. Translational research on Velzatinib resistance
3. De novo clinical prognostic biomarkers e.g. ctDNA

Neoadjuvant and adjuvant setting
1. Exploring the potential of Velzatinib in neoadjuvant and adjuvant GIST setting
2. Use of high sensitivity MRD tests for neo-adjuvant efficacy monitoring

Non-GIST Cancers with KIT Mutations
1. Exploring the potential of Velzatinib in non-GIST malignancies that have evidence of biology impacted by KIT signaling

[For Risvutatug Rezetecan (Ris-Rez) these include (updated October 2026):]

Small Cell Lung Cancer (SCLC)
   1.   High-Unmet-Need Sub-Populations in SCLC
         o   Distinct subpopulations with high unmet clinical need (e.g., transformed SCLC, brain metastasis, and other populations not adequately characterized in pivotal studies)

   2.   Emerging Treatment Sequence and Combinations
         o   Evaluation of Ris-Rez across the SCLC treatment continuum and in novel therapeutic combinations based on strong mechanistic rationale

Prostate Cancer
   1.   High-Unmet-Need Sub-Populations in Prostate Cancer
         o   Distinct subpopulations with high unmet clinical need (e.g., neuroendocrine prostate cancer and other populations not adequately characterized in pivotal studies).

   2.   Emerging Treatment Sequence and Combinations
         o   Evaluation of Ris-Rez across the prostate cancer treatment continuum and in novel therapeutic combinations based on strong mechanistic rationale

Solid tumors with high unmet need
   1.   High-Unmet-Need Thoracic or Genitourinary Tumors
         o   Evaluation of Ris-Rez in tumors for which there is a strong biological rationale for efficacy of Ris-Rez (e.g., neuroendocrine tumors)

   2.   Ris-Rez Mode of Action and Translational Science
         o   Investigations of the importance of B7-H3 as a cell surface target, and the mode-of-action of Ris-Rez in thoracic and genitourinary tumors (e.g., cytotoxic payload delivery and immunomodulatory effect)